Thermogenesis Holdings, INC 8-K filings

ThermoGenesis Holdings, Inc. has announced the immediate closure of its Indian subsidiary, TotipotentRx Cell Therapy Private Limited, effective December 31, 2024.

ThermoGenesis Holdings has replaced its independent auditor, Marcum LLP, with Simon & Edward LLP, effective August 1, 2024.

ThermoGenesis Holdings, Inc. announces the immediate resignation of its Chief Financial Officer, Jeffery Cauble, effective June 15, 2024.

ThermoGenesis Holdings has lost control of its subsidiary, ThermoGenesis Corp, after defaulting on a loan agreement with Boyalife Group (USA), Inc.

ThermoGenesis Holdings has received a default notice from Boyalife Group due to a missed interest payment, potentially leading to the seizure of its subsidiary, ThermoGenesis Corp.

ThermoGenesis Holdings converted $3 million of debt into equity, issuing 7,894,737 shares of common stock.

Three independent board members of ThermoGenesis Holdings, Inc. have resigned due to disagreements over company policies and potential conflicts of interest.

ThermoGenesis Holdings, Inc. has received a delisting notice from Nasdaq due to non-compliance with minimum stockholders' equity requirements, with trading suspension set for June 17, 2024.

ThermoGenesis Corp. and CBR Systems, Inc. have entered into a new three-year manufacturing and supply agreement for ThermoGenesis' AutoXpress System, replacing their prior agreement.

ThermoGenesis Holdings has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

ThermoGenesis Holdings converted $1.563 million of debt into 4,113,158 shares of common stock at $0.38 per share.

ThermoGenesis Holdings' Chief Operating Officer, Haihong Zhu, has resigned from the Board of Directors, effective March 8, 2024, but will continue in her role as COO.